Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Paying users zone. Data is hidden behind: .

  • Get 1-month access to Regeneron Pharmaceuticals Inc. for $15.99, or

  • get full access to the entire website for at least 3 months from $49.99.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey
Unlock

This is a one-time payment. There is no automatic renewal.

Regeneron Pharmaceuticals Inc. pages available today for free:

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Beginner level

Regeneron Pharmaceuticals Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Accounts payable
Accrued expenses and other current liabilities
Debt
Finance lease liabilities, current portion
Deferred revenue, Sanofi
Deferred revenue, other
Other liabilities, Sanofi
Current liabilities
Finance lease liabilities, excluding current portion
Deferred revenue, Sanofi
Deferred revenue, other
Other liabilities, Sanofi
Convertible senior notes
Other noncurrent liabilities
Noncurrent liabilities
Total liabilities
Preferred Stock, $.01 par value; issued and outstanding - none
Class A Stock, convertible, $.001 par value
Common Stock, $.001 par value
Additional paid-in capital
Retained earnings
Accumulated other comprehensive income (loss)
Treasury Stock, at cost
Stockholders’ equity
Total liabilities and stockholders’ equity

Based on: 10-Q (filing date: 2020-08-05), 10-Q (filing date: 2020-05-05), 10-K (filing date: 2020-02-07), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Regeneron Pharmaceuticals Inc.’s current liabilities as a percentage of total liabilities and stockholders’ equity decreased from Q4 2019 to Q1 2020 but then increased from Q1 2020 to Q2 2020 exceeding Q4 2019 level.
Noncurrent liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Regeneron Pharmaceuticals Inc.’s noncurrent liabilities as a percentage of total liabilities and stockholders’ equity decreased from Q4 2019 to Q1 2020 but then increased from Q1 2020 to Q2 2020 exceeding Q4 2019 level.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Regeneron Pharmaceuticals Inc.’s total liabilities as a percentage of total liabilities and stockholders’ equity decreased from Q4 2019 to Q1 2020 but then increased from Q1 2020 to Q2 2020 exceeding Q4 2019 level.
Stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity’s stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Regeneron Pharmaceuticals Inc.’s stockholders’ equity as a percentage of total liabilities and stockholders’ equity increased from Q4 2019 to Q1 2020 but then decreased significantly from Q1 2020 to Q2 2020.